Caroline Vickers, APRN
Adult Health · Denver, CONPI 1497127641
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 390 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 22.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,825 and has fallen 64.5% since, to $647 in 2025. Among adult health clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 390 payments — averaging $15.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Pfizer$648
- GSK$436
- Novo Nordisk$430
- Lilly USA, LLC$370
- Gilead$340
- plus $2K from 29 others
What the payments were for
- Food & beverage$5,982100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 105 | $1,346 |
| Pfizer | 30 | $648 |
| GSK | 28 | $436 |
| Novo Nordisk | 30 | $430 |
| Lilly USA, LLC | 21 | $370 |
| Gilead | 20 | $340 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $325 |
| Amgen | 22 | $299 |
| Biohaven Pharmaceutical Holding Company Ltd. | 17 | $179 |
| Johnson & Johnson | 9 | $157 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $139 |
| Teva Pharmaceuticals USA, Inc. | 7 | $135 |
| Mannkind Corporation | 1 | $120 |
| Biohaven Pharmaceuticals, Inc. | 12 | $118 |
| Astellas Pharma US Inc | 5 | $117 |
| AstraZeneca | 8 | $116 |
| Amneal Pharmaceuticals LLC | 6 | $87 |
| Boehringer Ingelheim | 6 | $87 |
| Upsher-smith Laboratories LLC | 3 | $61 |
| Abbott | 3 | $58 |
| Hologic Sales And Service, LLC | 2 | $50 |
| Neos Therapeutics, LP | 3 | $46 |
| Axsome Therapeutics, Inc. | 2 | $43 |
| Adlon Therapeutics L.p. | 2 | $39 |
| Merck | 2 | $36 |
| Novartis | 2 | $36 |
| Lundbeck LLC | 1 | $25 |
| Genentech USA, Inc. | 3 | $24 |
| Exact Sciences | 1 | $22 |
| Viiv Healthcare Company | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Antares Pharma, Inc. | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Althera Pharmaceuticals LLC | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AFREZZA$120
How this compares
$5,982 in reported general payments places this provider in the 95th percentile of 430 adult health providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 32 | $44,305 |
| OzempicSemaglutide | 35 | $41,358 |
| MyrbetriqMirabegron | 16 | $14,910 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 26 | $7,926 |
| Advair DiskusFluticasone Propion/Salmeterol | 11 | $4,972 |
| Atorvastatin Calcium | 279 | $3,702 |
| Rosuvastatin Calcium | 292 | $3,193 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 14 | $3,125 |
| Levothyroxine Sodium | 213 | $2,929 |
| Adacel TdapDiph,pertuss(Acell),tet Vac/Pf | 28 | $1,968 |
| Valsartan | 74 | $1,519 |
| Omeprazole | 85 | $1,485 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 47 | $1,450 |
| Losartan Potassium | 120 | $1,340 |
| SynthroidLevothyroxine Sodium | 27 | $1,210 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $87 | $44,30532 claims |
| Novo NordiskOzempic | $430 | $41,35835 claims |
| Astellas Pharma US IncMyrbetriq | $117 | $14,91016 claims |
| GSKArexvy, Shingrix | $436 | $11,05140 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $87 | $2,929213 claims |
| AbbVieSynthroid | $1,346 | $1,21027 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 430 adult health providers in Colorado.
Other adult health in Denver
- Toni StandleyDenver$23K
- Sarah MetzDenver$7K
- Rebecca RwubusisiDenver$5K
- Megan HillDenver$4K
- Peter PrutchDenver$3K
- Stefanie EymarAurora$36K
- Jamie ThompsonColorado Springs$31K
- Alexandra GravesAurora$18K
- Keri HalsemaAurora$17K
- Grace WorlandAurora$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.